Livzon Pharmaceutical Group (SZSE:000513) LT-Debt-to-Total-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Livzon Pharmaceutical Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Livzon Pharmaceutical Group's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.03.

Livzon Pharmaceutical Group's long-term debt to total assets ratio declined from Mar. 2023 (0.09) to Mar. 2024 (0.03). It may suggest that Livzon Pharmaceutical Group is progressively becoming less dependent on debt to grow their business.

Livzon Pharmaceutical Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Livzon Pharmaceutical Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Livzon Pharmaceutical Group LT-Debt-to-Total-Asset Chart

Livzon Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.08

0.07

Livzon Pharmaceutical Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.10	0.10	0.07	0.03

Livzon Pharmaceutical Group LT-Debt-to-Total-Asset Calculation

Livzon Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1621.804	/	25044.827
	=	0.06

Livzon Pharmaceutical Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	864.402	/	25189.696
	=	0.03

Livzon Pharmaceutical Group (SZSE:000513) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Livzon Pharmaceutical Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Livzon Pharmaceutical Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Livzon Pharmaceutical Group (SZSE:000513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Livzon Pharmaceutical Group Inc (SZSE:000513) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

01513:Hong Kong LP6:Germany

Address

38 Chuangye North Road, Headquarters Building, Jinwan District, Guangdong Province, Zhuhai, CHN, 519090

Website

https://www.livzon.com.cn

Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment which is pharmaceutical manufacturing.

Livzon Pharmaceutical Group (SZSE:000513) Headlines

No Headlines